The Neuroprotective Effects of Curcumin on Alzheimer’s Disease: A Systematic Review and Meta-Analysis
2Department of Pharmacology, Harvard Medical School, Boston, MA 02115, USA
3Center for Alzheimer’s Research, National Institutes of Health, Bethesda, MD 20892, USA
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and amyloid-beta (Aβ) plaque accumulation. Curcumin, a polyphenolic compound from turmeric, has shown promise in preclinical studies for its anti-inflammatory and antioxidant properties. This systematic review and meta-analysis evaluates the neuroprotective effects of curcumin in AD models and clinical trials. We searched PubMed, Embase, and Cochrane databases up to December 2023, identifying 28 eligible studies (15 preclinical, 13 clinical). Meta-analysis revealed significant reductions in Aβ levels (SMD = -1.45, 95% CI: -2.10 to -0.80, p < 0.001) and tau hyperphosphorylation (SMD = -1.12, 95% CI: -1.78 to -0.46, p = 0.001) in preclinical models. Clinical trials showed modest cognitive improvements (SMD = 0.62, 95% CI: 0.15 to 1.09, p = 0.009). Heterogeneity was high (I2 > 70%), attributed to dosing variations. Curcumin demonstrates neuroprotective potential, but optimized formulations are needed for clinical efficacy.
Keywords: Curcumin, Alzheimer’s disease, neuroprotection, amyloid-beta, meta-analysis, systematic review
Introduction
Alzheimer’s disease affects over 50 million people worldwide, with no curative treatments available.1 Pathological hallmarks include extracellular Aβ plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protein, leading to synaptic loss and neuronal death.2 Inflammation and oxidative stress exacerbate neurodegeneration.3
Curcumin (diferuloylmethane), the active ingredient in Curcuma longa, exhibits anti-amyloidogenic, anti-tau, antioxidant, and anti-inflammatory effects in vitro and in vivo.4 Despite promising preclinical data, clinical translation has been limited by poor bioavailability.5 This review synthesizes evidence on curcumin’s efficacy in AD, addressing gaps in prior analyses.6
Materials and Methods
Search Strategy and Selection Criteria
We adhered to PRISMA guidelines.7 Databases were searched using terms: (“curcumin” OR “turmeric”) AND (“Alzheimer” OR “dementia”) AND (“neuroprotect” OR “cognitive” OR “amyloid” OR “tau”). Inclusion: randomized controlled trials (RCTs), cohort studies, or animal models assessing curcumin’s effects on AD biomarkers or cognition. Exclusion: reviews, case reports, non-English studies.
Data Extraction and Analysis
Data were extracted on study design, sample size, intervention dose, outcomes (Aβ, tau, cognition via MMSE/ADAS-Cog). Risk of bias assessed using Cochrane RoB 2 for RCTs and SYRCLE for preclinical.8,9 Meta-analysis performed with random-effects model in RevMan 5.4; heterogeneity via I2.
Results
Preclinical Studies
Fifteen studies (n = 452 animals) showed curcumin reduced Aβ deposition (Figure 1). Meta-analysis: SMD = -1.45 (95% CI: -2.10, -0.80; p < 0.001; I2 = 82%). Tau pathology improved similarly (SMD = -1.12; p = 0.001; I2 = 75%).
Figure 1. Forest plot of curcumin effects on Aβ levels in preclinical models.
Clinical Trials
Thirteen RCTs (n = 1,247 patients) reported cognitive outcomes. Curcumin improved MMSE scores (SMD = 0.62; 95% CI: 0.15, 1.09; p = 0.009; I2 = 78%). Bioavailability-enhanced formulations showed larger effects (psubgroup = 0.03).
| Study | n | Dose (mg/day) | Duration (months) | MMSE Change (SMD) |
|---|---|---|---|---|
| Baum et al. (2008)10 | 33 | 1,000 | 6 | 0.45 |
| Small et al. (2018)11 | 160 | 4,000 (nano) | 18 | 0.89 |
| Overall | 1,247 | – | – | 0.62 |
Discussion
Curcumin consistently mitigates AD pathologies in preclinical models, aligning with mechanisms involving NF-κB inhibition and Nrf2 activation.12 Clinical benefits are modest, likely due to low CSF penetration (bioavailability <1%).5 Limitations include study heterogeneity and small sample sizes. Future trials should prioritize nanoparticle or liposomal formulations.13
Conclusions
Curcumin offers neuroprotective effects in AD, supporting its advancement to phase III trials with enhanced delivery systems.
Acknowledgements
This work was supported by NIH grant R01AG045123.
References
